These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 25687355)

  • 21. Increased survival with enzalutamide in prostate cancer after chemotherapy.
    Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS;
    N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Loriot Y; Fizazi K; de Bono JS; Forer D; Hirmand M; Scher HI
    Cancer; 2017 Jan; 123(2):253-262. PubMed ID: 27648814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.
    Quintela ML; Mateos LL; Estévez SV; Calvo OF; Herranz UA; Afonso FJ; Santomé L; Aparicio LA
    Cancer Treat Rev; 2015 Mar; 41(3):247-53. PubMed ID: 25638257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong Kong.
    Poon DMC; Wong KCW; Chan TW; Law K; Chan K; Lee EKC; Lee C; Chan M;
    Clin Genitourin Cancer; 2018 Oct; 16(5):402-412.e1. PubMed ID: 30126765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
    Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
    Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.
    Pilon D; Queener M; Lefebvre P; Ellis LA
    J Med Econ; 2016 Aug; 19(8):777-84. PubMed ID: 27031255
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
    Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
    Beer TM; Armstrong AJ; Rathkopf D; Loriot Y; Sternberg CN; Higano CS; Iversen P; Evans CP; Kim CS; Kimura G; Miller K; Saad F; Bjartell AS; Borre M; Mulders P; Tammela TL; Parli T; Sari S; van Os S; Theeuwes A; Tombal B
    Eur Urol; 2017 Feb; 71(2):151-154. PubMed ID: 27477525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzalutamide in European and North American men participating in the AFFIRM trial.
    Merseburger AS; Scher HI; Bellmunt J; Miller K; Mulders PF; Stenzl A; Sternberg CN; Fizazi K; Hirmand M; Franks B; Haas GP; de Bono J; de Wit R
    BJU Int; 2015 Jan; 115(1):41-9. PubMed ID: 25123978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
    Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
    J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
    de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
    Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The association between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: Exploratory analyses of AFFIRM and PREVAIL studies.
    Beer TM; Miller K; Tombal B; Cella D; Phung D; Holmstrom S; Ivanescu C; Skaltsa K; Naidoo S
    Eur J Cancer; 2017 Dec; 87():21-29. PubMed ID: 29096157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int; 2017 Aug; 120(2):168-184. PubMed ID: 28719114
    [No Abstract]   [Full Text] [Related]  

  • 37. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
    Armstrong AJ; Halabi S; Healy P; Alumkal JJ; Winters C; Kephart J; Bitting RL; Hobbs C; Soleau CF; Beer TM; Slottke R; Mundy K; Yu EY; George DJ
    Eur J Cancer; 2017 Aug; 81():228-236. PubMed ID: 28502694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
    Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
    Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.
    Ciccarese C; Nobili E; Grilli D; Casolari L; Rihawi K; Gelsomino F; Tortora G; Massari F
    Expert Rev Anticancer Ther; 2016 Jul; 16(7):681-96. PubMed ID: 27210425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial.
    Cella D; Ivanescu C; Holmstrom S; Bui CN; Spalding J; Fizazi K
    Ann Oncol; 2015 Jan; 26(1):179-185. PubMed ID: 25361992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.